pergolide has been researched along with Equine Diseases in 26 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (3.85) | 18.2507 |
| 2000's | 6 (23.08) | 29.6817 |
| 2010's | 11 (42.31) | 24.3611 |
| 2020's | 8 (30.77) | 2.80 |
| Authors | Studies |
|---|---|
| Fisch, J; Gehlen, H; Merle, R; Trachsel, DS | 1 |
| Durham, AE | 2 |
| Ihry, P; Schwarz, B | 1 |
| Adams, AA; Barker, VD; Bush, HM; Campana-Emard, AG; Grubbs, ST; Hart, KA; Loynachan, AT; Miller, AB | 1 |
| Benskey, MJ; Fortin, JS; Goudreau, JL; Howey, EB; Lookingland, KJ; Patterson, JS; Schott, HC | 1 |
| Ireland, JL; McGowan, CM; Tatum, RC | 1 |
| Banse, HE; Chelikani, PK; McFarlane, D; Whitehead, AE | 1 |
| Durham, AE; Hague, N; Menzies-Gow, NJ | 1 |
| Desjardins, I; Knoerr, F; Mosca, M; Pin, D; Randleff-Rasmussen, PK | 1 |
| Christen, G; Fouché, N; Frey, CF; Gerber, V; van der Kolk, JH | 1 |
| Bailey, SR; de Laat, MA; Hughes, KJ; Secombe, CJ; Sonis, JM; Stewart, AJ; Tan, R | 1 |
| Bockhorni, T; Kienzle, E | 1 |
| Doran, G; Edwards, S; Ireland, J; Rendle, DI | 1 |
| Beech, J; Durham, AE; Duz, M; Parkin, T; Rendle, DI | 1 |
| Banse, H; Knych, HK; Maxwell, LK; McFarlane, D | 1 |
| Davidson, GS; Davis, JL; Kirk, LM; Papich, MG | 1 |
| Cordes, B | 1 |
| McFarlane, D | 1 |
| Axon, JE; Spelta, CW | 1 |
| Desjardins, DR; Innerå, M; Petersen, AD; Rosser, EJ; Schott, HC; Steficek, BA | 1 |
| Divers, TJ; Erb, HN; Lamb, S; Nydam, DV; Perkins, GA; Schanbacher, B | 1 |
| Corazza, M; Maccheroni, M; Panzani, D; Sgorbini, M | 1 |
| Schott, HC | 1 |
| Doreste, F; Ferrer, O; González, J; Montoya, JA; Muñoz, MC | 1 |
5 review(s) available for pergolide and Equine Diseases
| Article | Year |
|---|---|
Efficacy of pergolide for the management of equine pituitary pars intermedia dysfunction: A systematic review.
Topics: Adrenocorticotropic Hormone; Animals; Horse Diseases; Horses; Pergolide; Pituitary Diseases; Pituitary Gland, Intermediate; Treatment Outcome | 2020 |
Equine pituitary pars intermedia dysfunction: current understanding and recommendations from the Australian and New Zealand Equine Endocrine Group.
Topics: Adrenocorticotropic Hormone; Animals; Australia; Dopamine Agonists; Horse Diseases; Horses; New Zealand; Pergolide; Pituitary Diseases; Pituitary Gland, Intermediate; Practice Guidelines as Topic; Risk Factors; Societies, Scientific | 2018 |
Therapeutics for Equine Endocrine Disorders.
Topics: Animals; Dopamine Agonists; Endocrine System Diseases; Horse Diseases; Horses; Pergolide | 2017 |
Equine pituitary pars intermedia dysfunction.
Topics: Aging; Animals; Diet; Dopamine Agonists; Female; Horse Diseases; Horses; Male; Pergolide; Pituitary Diseases; Pituitary Gland, Intermediate | 2011 |
Pituitary pars intermedia dysfunction: equine Cushing's disease.
Topics: Adrenocorticotropic Hormone; Animals; Dexamethasone; Dopamine Agonists; Female; Horse Diseases; Horses; Hydrocortisone; Male; Pergolide; Pituitary ACTH Hypersecretion; Pituitary Gland; Treatment Outcome | 2002 |
3 trial(s) available for pergolide and Equine Diseases
| Article | Year |
|---|---|
Effects of pituitary pars intermedia dysfunction and Prascend (pergolide tablets) treatment on endocrine and immune function in horses.
Topics: Adrenocorticotropic Hormone; Animals; Dose-Response Relationship, Drug; Female; Horse Diseases; Horses; Hypertrichosis; Male; Pergolide; Pituitary Diseases; Pituitary Gland, Intermediate | 2021 |
Pharmacokinetics and pharmacodynamics of pergolide mesylate after oral administration in horses with pituitary pars intermedia dysfunction.
Topics: Administration, Oral; Adrenocorticotropic Hormone; Animals; Area Under Curve; Horse Diseases; Horses; Pergolide; Pituitary Diseases; Pituitary Gland, Intermediate; Thyrotropin-Releasing Hormone | 2019 |
Pharmacokinetic and pharmacodynamic properties of pergolide mesylate following long-term administration to horses with pituitary pars intermedia dysfunction.
Topics: Adrenocorticotropic Hormone; Animals; Area Under Curve; Half-Life; Horse Diseases; Horses; Pergolide; Pituitary Diseases; Pituitary Gland, Intermediate | 2017 |
18 other study(ies) available for pergolide and Equine Diseases
| Article | Year |
|---|---|
Preliminary study on the effects of pergolide on left ventricular function in the horses with pituitary pars intermedia dysfunction.
Topics: Adrenocorticotropic Hormone; Animals; Dopamine Agonists; Horse Diseases; Horses; Pergolide; Pituitary Diseases; Pituitary Gland, Intermediate; Ventricular Function, Left | 2021 |
The effect of pergolide mesylate on adrenocorticotrophic hormone responses to exogenous thyrotropin releasing hormone in horses.
Topics: Adrenocorticotropic Hormone; Animals; Horse Diseases; Horses; Pergolide; Pituitary Diseases; Thyrotropin-Releasing Hormone | 2022 |
Accidental Overdose of Pergolide (Prascend) Followed by Loss of Appetite, Tachycardia, and Behavioral Abnormalities in a Pony Mare.
Topics: Animals; Appetite; Female; Heart Rate; Horse Diseases; Horses; Pergolide; Tachycardia | 2020 |
Restoring pars intermedia dopamine concentrations and tyrosine hydroxylase expression levels with pergolide: evidence from horses with pituitary pars intermedia dysfunction.
Topics: Aging; Animals; Dopamine; Dopamine Agonists; Horse Diseases; Horses; Pergolide; Pituitary Diseases; Pituitary Gland, Intermediate; Tyrosine 3-Monooxygenase | 2020 |
Markers of muscle atrophy and impact of treatment with pergolide in horses with pituitary pars intermedia dysfunction and muscle atrophy.
Topics: Animals; Horse Diseases; Horses; Muscular Atrophy; Pergolide; Pituitary Diseases; Pituitary Gland, Intermediate | 2021 |
Pergolide dosing compliance and factors affecting the laboratory control of equine pituitary pars intermedia dysfunction.
Topics: Animals; Female; Horse Diseases; Horses; Humans; Laboratories; Male; Medication Adherence; Pergolide; Pituitary Diseases; Pituitary Gland, Intermediate; Treatment Outcome | 2021 |
Successful medical treatment of an Aspergillus terreus mycetoma of the nostril/lip in a 16-year-old Fjord pony gelding with pituitary pars intermedia dysfunction.
Topics: Animals; Antifungal Agents; Aspergillosis; Aspergillus; Dopamine Agonists; Horse Diseases; Horses; Lip Diseases; Male; Mycetoma; Nose Diseases; Pergolide; Pituitary Diseases; Pituitary Gland, Intermediate; Potassium Iodide | 2017 |
Fecal strongyle egg counts in horses with suspected pre-clinical pituitary pars intermedia dysfunction before and after treatment with pergolide.
Topics: Adrenocorticotropic Hormone; Animals; Feces; Horse Diseases; Horses; Parasite Egg Count; Pergolide; Pituitary Diseases; Pituitary Gland, Intermediate; Prospective Studies; Strongyle Infections, Equine; Strongyloidea | 2018 |
[Nutrition of horses with equine pituitary pars intermedia dysfunction ("Cushing's syndrome") treated with pergolid - A field study].
Topics: Animals; Body Weight; Cushing Syndrome; Energy Intake; Horse Diseases; Horses; Nutrition Assessment; Pergolide | 2018 |
Investigation of single and paired measurements of adrenocorticotropic hormone for the diagnosis of pituitary pars intermedia dysfunction in horses.
Topics: Adrenocorticotropic Hormone; Animals; Dopamine Agonists; Female; Horse Diseases; Horses; Male; Pergolide; Pituitary Diseases; Pituitary Gland, Intermediate | 2015 |
Effects of compounding and storage conditions on stability of pergolide mesylate.
Topics: Administration, Oral; Animals; Dopamine Agonists; Drug Compounding; Drug Stability; Drug Storage; Horse Diseases; Horses; Light; Pergolide; Pharmaceutical Solutions; Pituitary ACTH Hypersecretion; Temperature; Time Factors | 2009 |
Supports compounding standards.
Topics: Animals; Drug Compounding; Drug Stability; Drug Storage; Horse Diseases; Horses; Pergolide | 2009 |
Case series of equine pituitary pars intermedia dysfunction in a tropical climate.
Topics: Animals; Dopamine Agonists; Female; Horse Diseases; Horses; Lameness, Animal; Male; Pergolide; Pituitary Diseases; Pituitary Gland, Intermediate; Prevalence; Prognosis; Treatment Outcome; Tropical Climate | 2012 |
Comparison of hair follicle histology between horses with pituitary pars intermedia dysfunction and excessive hair growth and normal aged horses.
Topics: Aging; Animals; Dopamine Agonists; Female; Hair; Hair Follicle; Horse Diseases; Horses; Male; Pergolide; Pituitary Diseases; Pituitary Gland, Intermediate | 2013 |
Plasma adrenocorticotropin (ACTH) concentrations and clinical response in horses treated for equine Cushing's disease with cyproheptadine or pergolide.
Topics: Adrenocorticotropic Hormone; Animals; Cushing Syndrome; Cyproheptadine; Drug Monitoring; Female; Horse Diseases; Horses; Luminescent Measurements; Male; Pergolide; Retrospective Studies; Sensitivity and Specificity | 2002 |
Equine cushing-like syndrome: diagnosis and therapy in two cases.
Topics: Animals; Cushing Syndrome; Dopamine Agonists; Female; Horse Diseases; Horses; Male; Pergolide; Treatment Outcome | 2004 |
FDA-CVM works to address concerns about pergolide supplies.
Topics: Animals; Drug Approval; Horse Diseases; Horses; Neuroprotective Agents; Pergolide; Pituitary Diseases; Pituitary Gland, Intermediate; United States | 2007 |
Pergolide treatment for Cushing's syndrome in a horse.
Topics: Animals; Cushing Syndrome; Dopamine Agonists; Horse Diseases; Horses; Hydrocortisone; Male; Pergolide | 1996 |